M. Buyse

M. Buyse, D. Nitti, M. Lise, 1991, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Multiple Prioritized Outcomes

M. Buyse, 2019, Wiley StatsRef: Statistics Reference Online.

FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

C. Tournigand, M. Buyse, A. de Gramont, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.

V. Sondak, M. Buyse, R. Carlson, 1996, Journal of the National Cancer Institute.

Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer

M. Buyse, 2009, International Journal of Clinical Oncology.

The role of colony stimulating factors in small cell lung cancer: why the question is still unsolved.

M. Buyse, P. Piedbois, V. Trillet-lenoir, 2002, Lung Cancer.

Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials

R. Peto, M. Buyse, R. Hills, 2001, The Lancet.

Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group.

R. Peto, M. Buyse, R. Gray, 1997, Journal of the National Cancer Institute.

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, Journal of the National Cancer Institute.

Meta-analysis: methods, strengths, and weaknesses.

M. Buyse, R. Carlson, P. Piedbois, 2000, Oncology.

Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.

A. Carrato, M. Buyse, J. Ajani, 2013, European journal of cancer.

A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.

M. Buyse, P. Philip, E. Cutsem, 2019, Future oncology.

A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel.

M. Buyse, I. Vergote, H. Bjermo, 2019, Gynecologic oncology.

Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.

M. Buyse, C. Geyer, N. Wolmark, 2011, Clinical breast cancer.

GENERAL THORACIC SURGERY LONG-TERM RESULTS OF LUNG METASTASECTOMY : PROGNOSTIC ANALYSES BASED ON 5206 CASES The International Registry of Lung Metastases

Ugo Pastorino, Marc Buyse, Philippe Girard, 2004 .

Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.

M Buyse, H Pass, M. Buyse, 1997, The Journal of thoracic and cardiovascular surgery.

Recent meta-analyses in colorectal cancer.

M. Buyse, P. Piedbois, 2000, Current opinion in oncology.

The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica

M. Buyse, S. Schreiber, 1995, Clinical Rheumatology.

Better characterisation of estrogen receptor (ER) positive luminal subtypes using genomic grade

J. Bergh, C. Sotiriou, S. Loi, 2005 .

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial

M. Buyse, M. Khasraw, S. Ackland, 2016, Journal of Neuro-Oncology.

The Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.The Effect of Debulking Surgery After Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer

M. Buyse, N. Colombo, S. Pecorelli, 1996 .

Non-inferiority trials in breast and non-small cell lung cancer: Choice of non-inferiority margins and other statistical aspects

M. Buyse, E. Saad, 2012, Acta oncologica.

NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC).

M. Buyse, K. Pogue-Geile, A. Srinivasan, 2018 .

Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

M. Buyse, J. Mackey, N. Robert, 2013 .

Designing phase II trials in cancer: a systematic review and guidance

M. Buyse, W. Gregory, J. Brown, 2011, British Journal of Cancer.

The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research.

I. Tannock, M. Stockler, M. Buyse, 2021, The Lancet. Oncology.

End points in advanced colon cancer clinical trials: a review and proposal.

D. Sargent, M. Buyse, R. Goldberg, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer.

M. Buyse, M. Parmar, V. Torri, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of anthracyclines in epithelial ovarian cancer.

M. Buyse, J. Vermorken, P. Harper, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

EuroCODE: a new approach to collaborative research in clinical oncology. EuroCODE Steering Committee.

O. Dalesio, M. Buyse, D. Machin, 1989, European journal of cancer & clinical oncology.

[Criteria and endpoints in advanced prostate cancer].

M. Buyse, P. Piedbois, 2012, Bulletin du cancer.

Neoadjuvant as Future for Drug Development in Breast Cancer—Letter

M. Buyse, E. Saad, T. Burzykowski, 2016, Clinical Cancer Research.

BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC->T) in women with Her-2/neu negative axillary lymph node positive early breast cancer.

M. Buyse, G. Sauter, J. Mackey, 2009 .

The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials

G. Molenberghs, M. Buyse, A. Alonso, 2008 .

Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!

L. Collette, M. Buyse, T. Burzykowski, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges in the methodology for the validation of surrogate endpoints in randomized trials

G. Molenberghs, M. Buyse, H. Geys, 2002 .

Oncology clinical trials

P. Müller, T. Lai, G. Rosner, 2013 .

The correlation structure of longitudinal measurements of vision in patients with macular degeneration

M. Buyse, T. Burzykowski, 2011, Pharmaceutical statistics.

RESEKTION VON LUNGENMETASTASEN: LANGZEITRESULTATE PROGNOSTISCHER FAKTOREN AUF DER BASIS VON 5206 FALLEN: THE INTERNATIONAL REGISTRY OF LUNG METASTASES

M. Buyse, R. Ginsberg, H. Pass, 1999 .

[Resection of lung metastases: long-term results and prognostic analysis based on 5206 cases--the International Registry of Lung Metastases].

M. Buyse, P. McCormack, R. Ginsberg, 1999, Zentralblatt fur Chirurgie.

Cancer clinical trials : methods and practice

M. Buyse, R. Sylvester, M. Staquet, 1986 .

Optimal combination therapy with Navoban (tropisetron) in patients with incomplete control of chemotherapy-induced nausea and vomiting. The Belgian Navoban Group.

M. Buyse, P. de Keyser, J. Canon, 1995, Anti-cancer drugs.

Reproducibility of monoamine metabolite measurements in human cerebrospinal fluid

M. Buyse, S. Goldman, J. Hildebrand, 1990, Acta neurologica Scandinavica.

Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.

E. Perez, M. Buyse, N. Wolmark, 2019, The Lancet. Oncology.

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial

B. Lambrecht, M. Buyse, C. Legrand, 2021, The Lancet Respiratory Medicine.

Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study

D. Maucort-Boulch, M. Buyse, J. Chiêm, 2020, Statistics in medicine.

Assessing long-term survival benefits of immune checkpoint inhibitors using the net survival benefit.

D. Maucort-Boulch, M. Buyse, S. Dalle, 2019, Journal of the National Cancer Institute.

Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC.

O. Dalesio, M. Buyse, N. Duez, 1989, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

M. Buyse, R. Ramlau, E. Stoelben, 2011, The Lancet. Oncology.

Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production.

M. Buyse, E. Sariban, Y. Beguin, 1998, Blood.

Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study.

M. Buyse, J. Cortes, B. Powell, 2019, Future oncology.

The role of intervention debulking surgery in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative Group study

M. Buyse, A. Maggioni, S. Pecorelli, 1996, International Journal of Gynecologic Cancer.

Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer

M. Buyse, L. Moretti, P. Flamen, 2021, Acta oncologica.

SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer.

M. Buyse, J. Sakamoto, K. Tanabe, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, European journal of cancer.

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial.

Joon-Oh Park, M. Buyse, Y. Bang, 2013 .

The ARCAD advanced colorectal cancer database-open for business.

D. Sargent, M. Buyse, R. Goldberg, 2012 .

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

R. Labianca, J. Meyerhardt, M. Buyse, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Intervention debulking surgery (IDS) does increase survival in advanced epithelial ovarian cancer (OC); an EORTC gynecological cancer cooperative group (GCCG) study

M. Buyse, N. Colombo, S. Pecorelli, 1993 .

Commentary on Bamat et al.

M. Buyse, E. Saad, 2020, Clinical trials.

Is FOB screening really the answer for lowering mortality in colorectal cancer?

M. Buyse, P. Boyle, P. Autier, 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

M. Buyse, G. Sauter, J. Mackey, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SAMIT: Preliminary safety data from a 2x2 factorial randomized phase III trial to investigate weekly paclitaxel (PTX) followed by oral fluoropyrimidines (FPs) versus FPs alone as adjuvant chemotherapy in patients (pts) with gastric cancer.

M. Buyse, J. Sakamoto, S. Morita, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An EORTC phase II study of sequential methotrexate-fluorouracil in locally advanced or metastatic gastric cancer. The EORTC Gastrointestinal Cancer Cooperative Group.

M. Buyse, N. Duez, G. Blijham, 1990, European journal of cancer.

An EORTC Gastrointestinal (GI) Group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancer

M. Buyse, N. Duez, H. Bleiberg, 1989, Medical oncology and tumor pharmacotherapy.

Multi-centre independent validation of a gene prognostic signature for patients with node-negative breast cancer (BC) - final results

Marc Buyse, Mauro Delorenzi, Christos Sotiriou, 2005 .

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

C. Bloomfield, M. Buyse, R. Larson, 2011, Blood.

Meta-analyses of published results are unreliable.

M. Buyse, R. Carlson, P. Piedbois, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia

M. Buyse, R. Schlenk, M. Heuser, 2015 .

Fraud in Clinical Trials

M. Buyse, S. Evans, 2014 .

Discussion: M K B Parmar and David Machin, monitoring clinical trials; Experience of, and proposals under consideration by the Cancer Therapy Committee of the British Medical Research Council

D. DeMets, S. Yusuf, S. Pocock, 1993 .

Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial.

M. Buyse, E. Sariban, C. Vermylen, 1996, Blood.

The value of preoperative radiotherapy in esophageal cancer: Results of a study of the E.O.R.T.C.

O. Dalesio, M. Buyse, P. Schlag, 1987, World Journal of Surgery.

A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy.

C. Desmedt, D. Larsimont, M. Buyse, 2009 .

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

Geert Molenberghs, Tomasz Burzykowski, Marc Buyse, 2000, The Lancet.

Re: A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer.

G. Molenberghs, M. Buyse, R. Carlson, 2001, Journal of the National Cancer Institute.

Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia

M. Buyse, P. Squifflet, J. Rowe, 2011, Trials.

Adjuvant Chemotherapy in Colorectal Cancer: Mournful, Hopeful Perpetual Motion Machine Heads to Dim Light at End of Tunnel-Reply

M. Buyse, T. Chalmers, A. Zeleniuch‐Jacquotte, 1989 .

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

Joon-Oh Park, M. Buyse, Y. Bang, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meta-analyses need time, collaboration, and funding.

M. Buyse, P. Piedbois, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The value of preoperative radiotherapy in esophageal cancer: results of a study by the EORTC.

O. Dalesio, M. Buyse, P. Schlag, 1988, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.

M. Buyse, S. Jagannath, R. Vij, 2015, Clinical lymphoma, myeloma & leukemia.

Multivariate Modelling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib

M. Buyse, D. Siegel, R. Vij, 2011 .

Erythropoietic Activity and Not With Inadequate Erythropoietin Production Anemia in Children With Cancer Is Associated With Decreased

M. Buyse, E. Sariban, A. Ferster, 2009 .

Anemia in Children With Cancer Is Associated With Decreased Erythropoietic Activity and Not With Inadequate Erythropoietin Production

M. Buyse, F. Corazza, E. Sariban, 1998 .

Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations.

R. Gelber, M. Buyse, M. Piccart, 2022, JAMA oncology.

Randomized phase II study of a combination of cisplatin (DDP), 5-fluorouracil (5-FU), and allopurinol (HPP) versus 5-FU in advanced colorectal carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group study.

M. Buyse, B. Vanderlinden, N. Duez, 1990, Cancer investigation.

Updated results at 6 year of the GERCOR C96.1 phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients

M. Buyse, O. Bouché, E. Gamelin, 2005 .

Abstract PD10-02: Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005)

M. Buyse, S. Paik, Chungyeul Kim, 2010 .

A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).

M. Buyse, Tae Won Kim, J. Sakamoto, 2016 .

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

D. Alberts, M. Buyse, L. Stewart, 1991, BMJ.

Secondary prevention of stroke: does dipyridamole add to aspirin?

M. Buyse, A. Lowenthal, 1994, Acta neurologica Belgica.

Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.

R. Labianca, M. Buyse, P. Rougier, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recent Trends in Adjuvant Therapy for Gastric Cancer

M. Buyse, D. Nitti, M. Lise, 1992 .

Adjuvant FAM2 in resectable gastric cancer.

M. Buyse, D. Nitti, M. Lise, 1989, Anticancer research.

Phase-III clinical trial of adjuvant FAM2 (5-FU, adriamycin and mitomycin C) vs control in resectable gastric cancer: a study of the EORTC Gastrointestinal Tract Cancer Cooperative Group.

M. Buyse, D. Nitti, M. Lise, 1988, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Phase I Cancer Clinical Trials: A Practical Guide

M. Buyse, E. Eisenhauer, C. Twelves, 2006 .

Assessing Treatment Benefit in Immuno-oncology

M. Buyse, E. Saad, T. Burzykowski, 2020, Statistics in Biosciences.

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

Gianluca Bontempi, Marc Buyse, Mauro Delorenzi, 2008, Clinical Cancer Research.

Generalized pairwise comparisons of prioritized outcomes in the two‐sample problem

M. Buyse, 2010, Statistics in medicine.

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.

D. Alberts, W. Sauerbrei, M. Buyse, 1998, British Journal of Cancer.

On the relationship between response to treatment and survival time.

M Buyse, M. Buyse, P. Piedbois, 1996, Statistics in medicine.

Alternative clinical end points in rectal cancer--are we getting closer?

M. Buyse, R. Glynne-Jones, S. Mawdsley, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of institutional participation in multicenter clinical trials.

M. Buyse, R. Sylvester, G. Bonadonna, 1981, The New England journal of medicine.

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.

Qingyuan Zhang, Kunwei Shen, Masakazu Toi, 2015, The Lancet. Oncology.

Common pitfalls in statistical analysis: Clinical versus statistical significance

M. Buyse, C. Pramesh, P. Ranganathan, 2015, Perspectives in clinical research.

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.

M. Buyse, T. Conroy, S. Leyvraz, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

P. Venugopal, M. Buyse, G. Gaidano, 2021, Cancer.

Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

John R. Mackey, Marc Buyse, Arlene Chan, 2009 .

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

M. Buyse, N. Robert, M. Gnant, 2016, The Lancet. Oncology.

Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

M. Buyse, J. Mackey, N. Robert, 2012, Clinical Cancer Research.

Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH

C. Sotiriou, C. Desmedt, D. Larsimont, 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Immunocytochemical markers in stage I lung cancer: relevance to prognosis.

M. Buyse, S. Ménard, U. Pastorino, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive value of TP 53 mutations in node-positive breast cancer patients treated with anthracycline-or anthracycline / taxane-based adjuvant therapy : results from the BIG 02-98 phase III trial

D. Larsimont, M. Buyse, M. Olivier, 2012 .

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

D. Larsimont, M. Buyse, M. Olivier, 2012, Breast Cancer Research.

Interim analysis of a phase III study on preoperative radiation therapy in resectable rectal carcinoma. Trial of the gastrointestinal tract cancer cooperative group of the European organization for research on treatment of cancer (EORTC)

O. Dalesio, M. Buyse, U. Metzger, 1985, Cancer.

Preoperative Radiotherapy as Adjuvant Treatment in Rectal Cancer: Final Results of a Randomized Study of the European Organization for Research and Treatment of Cancer (EORTC)

M. Buyse, J. Bosset, B. Nordlinger, 1988, Annals of surgery.

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Sung-Bae Kim, M. Buyse, M. Gnant, 2017, The Lancet. Oncology.

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.

M. Buyse, N. Colombo, S. Pecorelli, 1995, The New England journal of medicine.

Adjuvant treatment of stage I lung cancer with high-dose vitamin A.

M Buyse, M. Buyse, U. Pastorino, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Omics-based clinical trial designs

M. Buyse, S. Michiels, 2013, Current opinion in oncology.

Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.

R. Labianca, D. Sargent, M. Buyse, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.

D. Berry, A. D'Amico, P. Kantoff, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multifactorial approach to predicting resistance to anthracyclines.

Yuan Qi, Gianluca Bontempi, Marc Buyse, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women

Jack Cuzick, R. Collins, J. Crowley, 1988 .

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

Tomasz Burzykowski, Arturo Molina, Marc Buyse, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant trastuzumab in HER2-positive breast cancer.

Marc Buyse, Arlene Chan, Marek Pawlicki, 2011, The New England journal of medicine.

HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib

Joon-Oh Park, M. Buyse, G. Sauter, 2016, Molecular Cancer Therapeutics.

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials

M. Buyse, G. Sauter, J. Mackey, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

M. Buyse, G. Sauter, J. Mackey, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

R. Gelber, D. Larsimont, M. Buyse, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall survival bene fi t for sequential doxorubicin – docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer — 8-year results of the Breast International Group 02-98 phase III trial †

D. Larsimont, M. Buyse, G. Viale, 2013 .

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

M. Buyse, G. Sauter, N. Robert, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

R. Gelber, M. Buyse, A. Goldhirsch, 2008, Journal of the National Cancer Institute.

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

M. Buyse, J. Pignon, P. Rougier, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

C. Tournigand, D. Sargent, M. Buyse, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Daniel J Sargent, Daniel G Haller, Marc Buyse, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessing Treatment Benefit in Immuno-oncology

M. Buyse, E. Saad, T. Burzykowski, 2020 .

Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

C. Tournigand, M. Buyse, C. Bokemeyer, 2019, JAMA network open.

Chronological Trends in Progression-free, Overall and Post-progression Survival in First-line Therapy for Advanced Non-small-cell Lung Cancer.

M. Buyse, E. Saad, J. Jassem, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?

M. Buyse, E. Saad, J. Zalcberg, 2018, Journal of the National Cancer Institute.

Correcting the bias of the net benefit estimator due to right‐censored observations

D. Maucort-Boulch, L. Collette, M. Buyse, 2021, Biometrical journal. Biometrische Zeitschrift.

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma

M. Buyse, T. Conroy, M. Ychou, 2016, Oncotarget.

Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer

M. Buyse, W. Parulekar, P. Roy, 2015, British Journal of Cancer.

Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?

M. Buyse, E. Saad, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.

M. Buyse, M. Namer, F. Penault-Llorca, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of Surrogate Endpoints

Geert Molenberghs, Marc Buyse, Tomasz Burzykowski, 2006, Handbook of Statistical Methods for Randomized Controlled Trials.

Adjuvant Trastuzumab in HER 2-Positive Breast Cancer

M. Buyse, G. Sauter, J. Mackey, 2011 .

Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer

M. Buyse, N. Petrelli, R. Carlson, 1994 .

A perspective on surrogate endpoints in controlled clinical trials

G. Molenberghs, M. Buyse, A. Alonso, 2004, Statistical methods in medical research.

clinical trial Hydroxyurea for treatment of severe sickle cell anemia: a pediatric

M. Buyse, F. Corazza, C. Vermylen, 2011 .

Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

M. Buyse, J. Pignon, P. Rougier, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis.

M Buyse, S. Fox, A. Harris, 1997, The American journal of pathology.

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.

M. Buyse, P. Hérait, P. Piedbois, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer

M. Buyse, K. Gelmon, J. Mackey, 2014 .

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.

M. Buyse, J. Pignon, R. Carlson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges in breast cancer clinical trial design in the postgenomic era

C. Sotiriou, S. Loi, M. Buyse, 2004, Current opinion in oncology.

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

C. Sotiriou, C. Desmedt, D. Larsimont, 2011, The Lancet. Oncology.

Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer

C. Sotiriou, D. Larsimont, M. Buyse, 2013, PloS one.

Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors.

M. Buyse, E. Saad, A. Eggermont, 2020, European journal of cancer.

Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.

Kazuhiro Yoshida, M. Buyse, J. Sakamoto, 2014, The Lancet. Oncology.

Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy.

M. Buyse, J. Jassem, F. Piette, 2012, The oncologist.

Reply to R. Simon

M. Buyse, G. Sauter, D. Slamon, 2011 .

Comparison of prognostic gene expression signatures for breast cancer

Gianluca Bontempi, Marc Buyse, Benjamin Haibe-Kains, 2008, BMC Genomics.

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study

M. Buyse, N. Wolmark, A. Tan, 2013, Cancer Chemotherapy and Pharmacology.

Data sharing, year 1--access to data from industry-sponsored clinical trials.

Bartha M. Knoppers, Marc Buyse, Brian L. Strom, 2014, The New England journal of medicine.

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.

M. Buyse, L. Fallowfield, D. Cella, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists.

M Buyse, C Sotiriou, C. Sotiriou, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant therapy of colorectal cancer. Why we still don't know.

M. Buyse, T. Chalmers, A. Zeleniuch‐Jacquotte, 1988, JAMA.

Meta-analysis group in cancer: reappraisal of hepatic arterial infusion in the treatment of non resectable liver metastases from colorectal cancer

M. Buyse, 1996 .

Cell cycle parameters and prognosis of colorectal cancer.

M. Buyse, P. Galand, H. Bleiberg, 1984, European journal of cancer & clinical oncology.

An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with ifosfamide in advanced adenocarcinoma of the pancreas. EORTC Gastrointestinal Group.

M. Buyse, N. Duez, H. Bleiberg, 1989, European journal of cancer & clinical oncology.

Adjuvant therapy for colorectal cancer

M. Buyse, D. Nitti, M. Lise, 1987 .

Re-evaluation of the combination of CCNU, vincristine, and bleomycin in the treatment of malignant disseminated melanoma.

M. Buyse, J. Bernheim, R. Abele, 1981, Cancer treatment reports.

Tropisetron in the prevention of acute and delayed nausea and vomiting over six courses of emetogenic chemotherapy

M. Buyse, P. de Keyser, F. Hulstaert, 1998, Anti-cancer drugs.

Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting.

M. Buyse, P. de Keyser, J. Canon, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of dipyridamole in combination with anticoagulant therapy on survival and thromboembolic events in patients with prosthetic heart valves. A meta-analysis of the randomized trials.

M. Buyse, H. Pouleur, 1995, The Journal of thoracic and cardiovascular surgery.

Predictive Biomarkers and Personalized Medicine Analysis of Fc g Receptor IIIa and IIa Polymorphisms : Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

M. Buyse, J. Mackey, N. Robert, 2012 .

Design and analysis of clinical trials for predictive medicine

R. Simon, M. Buyse, 松井茂之, 2015 .

Cancer Clinical Trials: Methods and Practice.

M. Buyse, R. Sylvester, L. Freedman, 1985 .

Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission

Marc Buyse, Stefan Michiels, M. Buyse, 2011, Haematologica.

Neoadjuvant chemotherapy with cisplatin, methotrexate, bleomycin and vincristine (CABO) in patients with stage III and IV squamous cell carcinoma of the head and neck.

D. Larsimont, M. Buyse, P. van Houtte, 1989, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Individual- and trial-level surrogacy in colorectal cancer

Tomasz Burzykowski, Kevin Carroll, Marc Buyse, 2008, Statistical methods in medical research.

Exploring and validating surrogate endpoints in colorectal cancer

Junichi Sakamoto, Tomasz Burzykowski, Greg Yothers, 2008, Lifetime data analysis.

Artificial neural networks

Marc Buyse, Pascal Piedbois, M. Buyse, 1997, The Lancet.

Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.

M. Buyse, C. Bokemeyer, E. Van Cutsem, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regulatory versus Public Health Requirements in Clinical Trials

M. Buyse, 1993 .

Clinical Research after Drug Approval: What is Needed and What is Not

M. Buyse, G. Decoster, 1999 .

Phase IV Clinical Trials: Purposes, Design, and a Limited Place for Good Clinical Practice

M. Buyse, G. Decoster, 1995 .

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

C. Tournigand, M. Buyse, I. Chirivella, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Statistical Analysis of Survival and Disease Recurrence Data

M. Buyse, 1989 .

Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group.

M. Buyse, B. Pitt, D. Sharma, 2000, The American journal of cardiology.

Phase III design: principles.

M. Buyse, 2014, Chinese clinical oncology.

BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer

M. Buyse, J. Mackey, J. Canon, 2007 .

Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials.

M. Buyse, E. Saad, A. Katz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Daniel J Sargent, Greg Yothers, Daniel G Haller, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

M. Buyse, O. Bouché, A. de Gramont, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials.

M. Buyse, Y. Ohashi, J. Sakamoto, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

Marc Buyse, Pascal Piedbois, Thierry Andre, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†.

M. Buyse, M. Ychou, P. Rougier, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.

S Michiels, M Buyse, S Marguet, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Unbiasedness and efficiency of non-parametric and UMVUE estimators of the probabilistic index and related statistics

G. Molenberghs, M. Buyse, M. Aerts, 2020, Statistical methods in medical research.

Interim analyses, stopping rules and data monitoring in clinical trials in Europe.

M. Buyse, 1993, Statistics in medicine.

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.

Tomasz Burzykowski, Marc Buyse, Stefan Michiels, 2009, The Lancet. Oncology.

The search for surrogate endpoints for immunotherapy trials.

M. Buyse, E. Saad, T. Burzykowski, 2018, Annals of translational medicine.

Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation

Marc Buyse, Tomasz Burzykowski, M. Buyse, 2006, Pharmaceutical statistics.

The validation of surrogate end points by using data from randomized clinical trials: a case‐study in advanced colorectal cancer

Geert Molenberghs, Tomasz Burzykowski, Marc Buyse, 2004 .

Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.

Brian Bot, Greg Yothers, Qian Shi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized clinical trials in surgical oncology.

M. Buyse, 1991, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Improving public health by improving clinical trial guidelines and their application

Adam Cohen, Jeroen J. Bax, Marc Buyse, 2017, European heart journal.

Evaluation of treatment efficacy using a Bayesian mixture piecewise linear model of longitudinal biomarkers

Brian Neelon, Marc Buyse, Dai Feng, 2015, Statistics in medicine.

Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial).

L. Zelek, M. Buyse, H. Kobeiter, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Statistical challenges in the evaluation of surrogate endpoints in randomized trials.

Geert Molenberghs, Tomasz Burzykowski, Helena Geys, 2002, Controlled clinical trials.

Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.

Daniel J Sargent, Qian Shi, Marc Buyse, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.

C. Tournigand, M. Buyse, I. Chirivella, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Using t he E xpected S urvival t o E xplain D ifferences Between t he R esults o f R andomized T rials: A C ase i n A dvanced O varian C ancer

M. Buyse, M. Parmar, V. Torri, 2003 .

A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses

Tomasz Burzykowski, Federico Rotolo, Marc Buyse, 2019, Statistical methods in medical research.

Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9

M. Buyse, N. Wolmark, A. Tan, 2015, Breast Cancer Research and Treatment.

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.

M. Buyse, E. Saad, P. Hoff, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1).

M. Buyse, A. de Gramont, T. André, 2010, Clinical colorectal cancer.

Assessment of Statistical Heterogeneity in the PLATO Trial

I. Marschner, M. Buyse, 2011, Cardiology.

Meta-analyses based on abstracted data: a step in the right direction, but only a first step.

M. Buyse, P. Piedbois, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

Tomasz Burzykowski, Marc Buyse, Laura Biganzoli, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meta-analysis of randomized clinical trials in the era of individual patient data sharing

M. Buyse, J. Sakamoto, K. Oba, 2018, International Journal of Clinical Oncology.

Progression-free survival ratio as end point for phase II trials in advanced solid tumors.

C. Tournigand, M. Buyse, R. Mick, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy in colorectal cancer.

M. Buyse, U. Metzger, A. Gérard, 1989, Anticancer research.

Current Issues in Adjuvant Treatment of Stage II Colon Cancer

D. Sargent, M. Buyse, C. Boni, 2006, Annals of Surgical Oncology.

Better characterization of estrogen receptor (ER) positive luminal subtypes of breast cancer using genomic grade.

J. Bergh, C. Sotiriou, S. Loi, 2005 .

Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, Journal of the National Cancer Institute.

Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.

M. Buyse, E. Saad, Rod S. Taylor, 2015, Journal of clinical epidemiology.

Cell kinetic indicators of premalignant stages of colorectal cancer

M. Buyse, P. Galand, H. Bleiberg, 1985, Cancer.

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

J. Forbes, M. Buyse, G. Sauter, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Data fraud in clinical trials.

Marc Buyse, Stephen L George, M. Buyse, 2015, Clinical investigation.

Linear mixed‐effects models for central statistical monitoring of multicenter clinical trials

C Legrand, L Desmet, D Venet, 2014, Statistics in medicine.

Cyclophosphamide Plus Cisplatin Versus Cyclophosphomide, Doxorubicin, and Cisplatin Chemotherapy of Ovarian-carcinoma - a Metaanalysis

Marc Buyse, M. Buyse, 1991 .

Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer.

M Buyse, M. Buyse, R. Schilsky, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A unifying approach for surrogate marker validation based on Prentice's criteria

Geert Molenberghs, Helena Geys, Tony Vangeneugden, 2006, Statistics in medicine.

Simplified hierarchical linear models for the evaluation of surrogate endpoints

Geert Molenberghs, Russell D. Wolfinger, José Cortiñas Abrahantes, 2003 .

Validation of a longitudinally measured surrogate marker for a time-to-event endpoint

Geert Molenberghs, Luc Bijnens, Tomasz Burzykowski, 2003 .

A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).

M. Buyse, S. Gettinger, T. Lynch, 2013 .

Adaptive Randomization of Neratinib in Early Breast Cancer.

Tomasz Burzykowski, Marc Buyse, M. Buyse, 2016, The New England journal of medicine.

Treatment of patients with irresectable liver metastases from colorectal cancer by chemo‐occlusion with degradable starch microspheres

M. Buyse, N. Duez, J. Arnaud, 1994, The British journal of surgery.

149ONeratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial

M. Buyse, M. Gnant, H. Iwata, 2017 .

Response to the letter to the editor 'Reply to "Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents" by H. K. van Halteren'.

M. Buyse, E. Saad, 2016, Annals of Oncology.

Statistics in oncology.

M. Buyse, J. Abrams, S. Land, 2008, Journal of Clinical Oncology.

Predicting Treatment Effect from Surrogate Endpoints and Historical Trials: An Extrapolation Involving Probabilities of a Binary Outcome or Survival to a Specific Time

D. Sargent, M. Buyse, S. Baker, 2012, Biometrics.

Fluoropyrimidines in Advanced Colorectal Cancer

M. Buyse, P. Piedbois, 2003 .

Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer

L. Zelek, M. Buyse, P. Piedbois, 2002, Expert review of anticancer therapy.

Economic implications of hepatic arterial infusion versus intravenous chemotherapy or symptom palliation in the treatment of nonresectable colorectal liver metastases. Meta-Analysis Group In Cancer.

V. Sondak, M. Buyse, R. Carlson, 1999, Critical reviews in oncology/hematology.

Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer.

M. Buyse, N. Wolmark, P. Piedbois, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer.

V. Sondak, M. Buyse, R. Carlson, 1997, Journal of the National Cancer Institute.

Final results of a meta-analysis testing HER2 and topoisomerase IIα genes as predictors of incremental benefit from anthracyclines in breast cancer.

C. Desmedt, D. Larsimont, M. Buyse, 2010 .

Data Sharing - Is the Juice Worth the Squeeze?

Bartha M Knoppers, B. Knoppers, M. Buyse, 2016, The New England journal of medicine.

Common pitfalls in statistical analysis: The perils of multiple testing

Priya Ranganathan, Marc Buyse, C. S. Pramesh, 2016, Perspectives in clinical research.

Statistical evaluation of surrogate endpoints with examples from cancer clinical trials

Geert Molenberghs, Tomasz Burzykowski, Marc Buyse, 2016, Biometrical journal. Biometrische Zeitschrift.

Taxanes in the adjuvant treatment of breast cancer: why not yet?

M. Buyse, M. Piccart, L. Duchateau, 2001, Journal of the National Cancer Institute. Monographs.

FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study.

C. Tournigand, M. Buyse, A. Figer, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

The ARCAD clinical trials program: an update and invitation.

Daniel J Sargent, Marc Buyse, Alastair Matheson, 2012, The oncologist.

Validation of biomarkers as surrogates for clinical endpoints

G. Molenberghs, M. Buyse, H. Geys, 2003 .

Meta-analyses, use and misuse.

M. Buyse, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of Fraud in a Clinical Trial Using Unsupervised Statistical Monitoring

M. Buyse, H. Schumacher, H. Lomp, 2021, Therapeutic Innovation & Regulatory Science.

The impact of data errors on the outcome of randomized clinical trials

M. Buyse, E. Saad, C. Punt, 2017, Clinical trials.

Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial

M. Buyse, C. Legrand, T. Burzykowski, 2015, Gastric Cancer.

Ensuring trial validity by data quality assurance and diversification of monitoring methods

Douglas G Altman, Marc Buyse, Frank E Harrell, 2008, Clinical trials.

The trials of Dr. Bernard Fisher: a European perspective on an American episode.

D. Sackett, O. Dalesio, R. Doll, 1997, Controlled clinical trials.

BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC).

M. Buyse, F. André, H. Burris, 2012 .

Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments

M. Buyse, P. Piedbois, 2008, Current opinion in oncology.

The ARCAD advanced colorectal cancer database--open for business.

D. Sargent, M. Buyse, R. Goldberg, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes

Geert Molenberghs, Helena Geys, Marc Buyse, 2002 .

Tumor-size-based endpoints as surrogates for overall survival in the ARCAD Advanced Colorectal Cancer Database.

D. Sargent, M. Buyse, E. Saad, 2017 .

Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.

C. Tournigand, D. Sargent, M. Buyse, 2014 .

Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.

D. Sargent, M. Buyse, J. Hecht, 2014 .

Progress in the medical treatment of advanced colorectal cancer

M. Buyse, E. Fabre-Guillevin, P. Piedbois, 2003, Expert review of anticancer therapy.

Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients

C. Sotiriou, C. Desmedt, A. Harris, 2006, International journal of cancer.

On the relationship between the causal‐inference and meta‐analytic paradigms for the validation of surrogate endpoints

Geert Molenberghs, Tomasz Burzykowski, Ariel Alonso, 2015, Biometrics.

Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials

M. Buyse, J. Pignon, V. Georgoulias, 2013, BMJ Open.

Prentice's Approach and the Meta‐Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints

Geert Molenberghs, Ziv Shkedy, José Cortiñas Abrahantes, 2004, Biometrics.

Analysis of clinical trial outcomes: some comments on subgroup analyses.

M. Buyse, M E Buyse, 1989, Controlled clinical trials.

Issues of efficiency in combining proportions of deaths from several clinical trials.

M. Buyse, L. Ryan, 1987, Statistics in medicine.

Common pitfalls in statistical analysis: “No evidence of effect” versus “evidence of no effect”

M. Buyse, C. Pramesh, P. Ranganathan, 2015, Perspectives in clinical research.

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.

M. Buyse, M. Gnant, H. Iwata, 2023, European journal of cancer.

The potential and perils of observational studies.

S. Vansteelandt, M. Buyse, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of follow-up on generalized pairwise comparisons for estimating the irinotecan benefit in advanced/metastatic gastric cancer.

M. Buyse, X. Paoletti, O. Bouché, 2021, Contemporary clinical trials.

A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons

L. Collette, M. Buyse, C. Legrand, 2020, Biometrical journal. Biometrische Zeitschrift.

Neratinib after trastuzumab in patients with HER2-positive breast cancer Reply

M. Buyse, A. Chan, B. Yao, 2016 .

Validation of Surrogate Endpoints in Advanced Solid Tumours: Systematic Review of Statistical Methods, Results, and Implications for Policy Makers

M. Buyse, P. Tappenden, S. Davis, 2013 .

Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply.

M. Buyse, A. Chan, B. Yao, 2016, The Lancet. Oncology.

'Statistical controversies in clinical research': a new series in Annals of Oncology.

M. Buyse, J. Soria, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized Designs for Early Trials of New Cancer Treatments—An Overview

M. Buyse, 2000 .

The case of loose inclusion criteria in clinical trials.

M. Buyse, 1990, Acta chirurgica Belgica.

Fluoropyrimidines in Advanced Colorectal Cancer: A Review of Six Consecutive Meta-Analyses

M. Buyse, P. Piedbois, 2002 .

Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer

M. Buyse, A. Piga, C. Köhne, 2001, British Journal of Cancer.

Meta-analysis of randomized clinical trials in cancer.

M. Buyse, 1993, Gan to kagaku ryoho. Cancer & chemotherapy.

What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin? Advanced Colorectal Meta-analysis Project.

M. Buyse, P. Piedbois, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Generalized Pairwise Comparisons

Marc Buyse, M. Buyse, 2019, Wiley StatsRef: Statistics Reference Online.

The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma

D. Maucort-Boulch, M. Buyse, J. Péron, 2019, Pancreas.

Generalized Pairwise Comparisons for Prioritized Outcomes

Marc Buyse, Julien Péron, M. Buyse, 2021 .

Reformulating the hazard ratio to enhance communication with clinical investigators

M. Buyse, M. Buyse, 2008, Clinical trials.

Update in methodology and conduct of cancer clinical trials.

M. Buyse, E. Eisenhauer, P. Therasse, 2006, European journal of cancer.

Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question.

M. Buyse, E. Saad, T. Burzykowski, 2017, JAMA oncology.

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy

A. Schneeweiss, R. Gelber, M. Buyse, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Using an interim analysis based exclusively on an early outcome in a randomized clinical trial with a long‐term clinical endpoint

M. Buyse, C. Legrand, T. Burzykowski, 2021, Pharmaceutical statistics.

Open science: The open clinical trials data journey

Marc Buyse, Frank Rockhold, Christina Bromley, 2019, Clinical trials.

Use of the Beta-Binomial Model for Central Statistical Monitoring of Multicenter Clinical Trials

M. Buyse, C. Legrand, T. Burzykowski, 2017 .

A Statistical Approach to Risk-Based Monitoring

Marc Buyse, M. Buyse, 2014 .

The effect of body mass index (BMI) on disease-free and overall survival in node-positive breast cancer treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

R. Gelber, M. Buyse, W. McCaskill-Stevens, 2008 .

Statistical controversies in clinical research: statistical significance-too much of a good thing ….

M. Buyse, W. Eiermann, F. André, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients

Gianluca Bontempi, Y. Qi, C. Sotiriou, 2013, Genomics data.

Interim analysis of a double-blind phase-III clinical trial of adjuvant levamisole versus control in resectable Dukes-C colon cancer: a study of the EORTC Gastrointestinal Tract Cancer Cooperative Group.

M. Buyse, B. Nordlinger, N. Duez, 1988, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Sung-Bae Kim, M. Buyse, N. Robert, 2019, Breast Cancer Research.

1375P Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

M. Buyse, M. Parmar, D. Dearnaley, 2022, Annals of Oncology.

Simulation studies of surrogate endpoint validation using single trial and multitrial statistical approaches.

M. Buyse, K. Johnson, G. Wells, 2007, The Journal of rheumatology.

Progression-free survival (PFS) as a surrogate for overall survival (OS) in patients with advanced colorectal cancer: An analysis of 3159 patients randomized in 11 trials

Tomasz Burzykowski, J. P. Pignon, Kevin Carroll, 2005 .

Authors’ Reply to Schoenfeld: “Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors”

M. Buyse, E. Saad, S. Michiels, 2017, Drugs.

The Net Benefit of a treatment should take the correlation between benefits and harms into account.

M. Buyse, E. Saad, J. Chiêm, 2021, Journal of clinical epidemiology.

Surrogates for Clinical Endpoints

M. Buyse, 2003 .

Fraud in clinical trials: complex problem, simple solutions?

M. Buyse, J. Sakamoto, 2016, International Journal of Clinical Oncology.

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

E. Rutgers, S. Loi, M. Buyse, 2006, Nature Clinical Practice Oncology.

Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.

D. Sargent, M. Buyse, J. Pignon, 2010, JAMA.

E23. Statistical issues in the validation of biomarkers and surrogate endpoints

M. Buyse, 2010 .

Towards validation of statistically reliable biomarkers

Marc Buyse, M. Buyse, 2007 .

A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000).

L. Zelek, M. Buyse, P. Piedbois, 2014, European journal of cancer.

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

A. Schneeweiss, R. Gelber, M. Buyse, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene Expression Pro fi ling in Breast Cancer : Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

C. Sotiriou, S. Loi, B. Haibe-Kains, 2006 .

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Sung-Bae Kim, M. Buyse, N. Robert, 2019, Breast Cancer Research.

Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1,500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC).

C. Sotiriou, S. Loi, B. Haibe-Kains, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular forecasting of breast cancer: time to move forward with clinical testing.

E. Rutgers, C. Sotiriou, S. Loi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Controlled Clinical Trial for the Treatment of Patients with Inopérable Esophageal Carcinoma: A Study of the EOR TC Gastrointestinal Tract Cancer Coopérative Group

M. Buyse, N. Duez, M. Gignoux, 2016 .

Palliative therapy of inoperable oesophageal carcinoma with radiotherapy and methotrexate: final results of a controlled clinical trial.

O. Dalesio, M. Buyse, N. Duez, 1989, International journal of radiation oncology, biology, physics.

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

M. J. van de Vijver, C. Sotiriou, S. Loi, 2006, Journal of the National Cancer Institute.

FRIEDAL FOR THE INTERNATIONAL REGISTRY OF LUNG METASTASES: LONG- TERM RESULTS OF LUNG METASTASECTOMY: PROGNOSTIC ANALYSES BASED ON 5, 206 CASES

M. Buyse, U. Pastorino, 1997 .

Limitations of adaptive clinical trials.

M. Buyse, 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

A biostatistical tribute to Ignaz Philip Semmelweis.

M. Buyse, 1997, Statistics in Medicine.

A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration.

M. Buyse, J. Slakter, C. Wykoff, 2023, Ophthalmology.

FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

C. Tournigand, M. Buyse, A. de Gramont, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.

M. Buyse, C. Bokemeyer, E. Van Cutsem, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database.

D. Sargent, M. Buyse, C. Fuchs, 2013 .

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.

M. Buyse, J. Pignon, T. Pajak, 2009, The Lancet. Oncology.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

E. Rutgers, E. Winer, J. Cuzick, 2015, The Lancet.

Meta-analysis of randomized clinical trials in the era of individual patient data sharing

M. Buyse, J. Sakamoto, K. Oba, 2018, International Journal of Clinical Oncology.

Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward.

M. Drummond, M. Buyse, G. Rasi, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials

Qian Shi, Tomasz Burzykowski, Brian M. Bot, 2011, Comput. Stat. Data Anal..

Statistical Validation of Surrogate Endpoints: Problems and Proposals

Geert Molenberghs, Tomasz Burzykowski, Helena Geys, 2000 .

Impact of on-site initiation visits on patient recruitment and data quality in a randomized trial of adjuvant chemotherapy for breast cancer

M. Buyse, E. Fabre-Guillevin, P. Piedbois, 2006, Clinical trials.

Data sharing, year 1--access to data from industry-sponsored clinical trials.

B. Knoppers, M. Buyse, B. Strom, 2014, The New England journal of medicine.

Generalized pairwise comparisons of prioritized outcomes in the two‐sample problem

M. Buyse, 2010, Statistics in medicine.

Surrogate end points: when should they be used?

Geert Molenberghs, Tomasz Burzykowski, Marc Buyse, 2013 .

Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803.

M Buyse, D J Sargent, D. Sargent, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

C. Bloomfield, M. Buyse, R. Larson, 2011, Blood.

L. Zelek, M. Buyse, P. Piedbois, 2014, European journal of cancer.

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.

Joon-Oh Park, M. Buyse, Y. Bang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials

G. Molenberghs, M. Buyse, T. Burzykowski, 2010, Statistical methods in medical research.

Multifactorial approach to predicting resistance to anthracyclines.

Gianluca Bontempi, Y. Qi, C. Sotiriou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The value of preoperative radiotherapy in esophageal cancer: Results of a study of the E.O.R.T.C.

O. Dalesio, M. Buyse, P. Schlag, 1987, World Journal of Surgery.

NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).

M. Buyse, T. Julian, S. Paik, 2012 .

Clinical Trials in the Genomic Era

G. Molenberghs, M. Buyse, T. Burzykowski, 2014 .

Cornerstones of a well-designed phase III trial

M. Buyse, 2003 .

Relationship Between Intestinal Function and Exposure to Sorafenib and Sunitinib in Cancer Patients

M. Buyse, O. Mir, F. Goldwasser, 2012 .